A Phase 2, Open Label, Pilot Study to Examine the Use of Rivaroxaban Plus Aspirin vs. Clopidogrel Plus Aspirin for the Prevention of Restenosis After Infrainguinal Percutaneous Transluminal Angioplasty for Critical Limb Ischemia
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs Rivaroxaban (Primary) ; Aspirin; Clopidogrel
- Indications Peripheral arterial disorders; Peripheral artery restenosis
- Focus Adverse reactions
- Acronyms RIVAL-PAD
- 19 Jul 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 19 Mar 2018 Planned End Date changed from 1 Dec 2017 to 1 Mar 2019.